Relationship Between Modelling Approach and Reported Outcomes: Case Studies of Models for the Treatment of Schizophrenia von von Schéele, B, Mauskopf, J.A, Brodtkorb, T.H, Ainsworth, C, Galani Berardo, C, Patel, A

Volltext

PT27 How Much Does TLV Value Rarity? A Review of Reimbursement Decisions on Orphan Drugs in Sweden from 2017 through 2022 von Lanne, G., Kinderas, M., Ling, C., Brodtkorb, T.H.

Volltext

PBI30 BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE von Carrico, J., Jia, X., Zhao, Y., Zhang, J., Brodtkorb, T.H., Mendelsohn, A.B., Lowry, S., Wu, J.J., Feldman, S.R., Armstrong, A.W.

Volltext

PNS220 SUBMISSION PROCESS AND REQUIREMENTS OF NORDIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES FOR HOSPITAL DRUGS: IMPLICATIONS FOR MARKET ACCESS STRATEGY von Aronsson, M., Ling, C., Stevenson, A., Brodtkorb, T.H.

Volltext

PRM83 - Relationship Between Modelling Approach and Reported Outcomes: Case Studies of Models for the Treatment of Schizophrenia von von Schéele, B., Mauskopf, J.A., Brodtkorb, T.H., Ainsworth, C., Galani Berardo, C., Patel, A.

Volltext